The goal of this study is to develop a controlled methotrexate delivery system that releases its content by a target specific stimulus. To accomplish this, both methotrexate and an engineered channel protein (MscL) were incorporated into DOPC/CH/DSPE-PEG liposomes, providing a controlled drug delivery system. Reconstitution and encapsulation methods were optimized in order to ensure optimal channel gating activity and high drug:lipid ratio. At the optimal conditions, a 95% release of MTX could be reached.